Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead Hit With Another NASH Setback As Selonsertib Fails In First Phase III

Feb 11 2019

• By Joseph Haas

Down arrow on pavement

Related Content

Genfit May Be Gaining An Edge In NASH Race

Oct 26 2017

Intercept Hopes Statin Trial Will Lessen Ocaliva's Perceived CV Risk

Mar 22 2017

Allergan’s Two-Year NASH Data Fail To Show Fibrosis Benefit

Sep 22 2017

New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib

Apr 20 2018

Gilead’s FXR Agonist Posts Questionable Results In NASH, But Offers Hope In PSC

Nov 10 2018

Related Companies

Gilead Sciences, Inc.

Intercept Pharmaceuticals, Inc.

Allergan plc

Genfit SA

Additional Topics

Clinical Trials Research & Development Companies Liver & Hepatic BioPharmaceutical

More from Alimentary/Metabolic

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window